National Systemic Anti-Cancer Therapy (SACT) consent forms – forms for gynaecological cancers published

By BOPA Committee on 5 January 2017

The regimen-specific consent forms for gynaecological cancers have been published on the Cancer Research UK (CRUK) website.  There are 24 forms for this tumour group:
 
  • BEP (5 day)
  • Bevacizumab
  • Carboplatin
  • Carboplatin-Etoposide
  • Carboplatin-Paclitaxel
  • Cisplatin
  • Cisplatin + Radiotherapy
  • Cisplatin-Etoposide
  • Cisplatin-Fluorouracil
  • Cisplatin-Fluorouracil + Radiotherapy
  • Cisplatin-Paclitaxel
  • Cisplatin-Topotecan
  • Doxorubicin
  • Doxorubicin-Cisplatin
  • EP (Etoposide-Cisplatin)
  • Etoposide (oral)
  • Gemcitabine
  • Gemcitabine-Carboplatin
  • Gemcitabine-Cisplatin
  • Liposomal doxorubicin (Caelyx®)
  • Liposomal doxorubicin (Caelyx®) - Carboplatin
  • Olaparib
  • Paclitaxel (day 1, 8 & 15)
  • Topotecan (IV)
 
Please visit www.cruk.org/sact_consent to view and download the forms.  Other forms, national guidance on consent for SACT, and further information is also available via www.cruk.org/sact_consent.
 
The National Chemotherapy Board published guidance on consent for SACT in July 2016 and recommends use of the regimen-specific forms in the UK.  The forms have been produced with support from CRUK.
 
Please do not hesitate to contact Rena Chauhan (Oncology Pharmacist – CRUK information lead, Guy’s and St. Thomas’ NHS Foundation Trust) if you have any queries: rena.chauhan@gstt.nhs.uk.
 
Rena Chauhan
4 January 2017
 
Close
Close
Close